Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

282868

Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid leukemia (AML) who have achieved complete remission after intensive induction chemotherapy. The approval is for people in remission with or without complete blood count recovery, who are not eligible for a stem cell transplant. This decision follows U.S. Food and Drug Administration approval of Onureg, by Bristol Myers Squibb, for the same indication in September. “While the majority of…

You must be logged in to read/download the full post.